GO
Loading...

Gilead Sciences Inc

More

  • Final Glance: Biotechnology companies Monday, 22 Sep 2014 | 6:03 PM ET

    Amgen Inc. fell $1.83 or 1.3 percent, to $142.18. Biogen Idec rose$. 52 or. 2 percent, to $329.76. Celgene Corp. fell $1.66 or 1.8 percent, to $92.19.

  • Midday Glance: Biotechnology companies Monday, 22 Sep 2014 | 2:12 PM ET

    Amgen Inc. fell $2.75 or 1.9 percent, to $141.26. Biogen Idec fell $2.59 or. 8 percent, to $326.65. Celgene Corp. fell $1.94 or 2.1 percent, to $91.91.

  • Early Glance: Biotechnology companies Monday, 22 Sep 2014 | 11:05 AM ET

    Amgen Inc. fell $1.69 or 1.2 percent, to $142.32. Biogen Idec fell $2.41 or. 7 percent, to $326.83. Celgene Corp. fell $1.44 or 1.5 percent, to $92.41.

  • Final Glance: Biotechnology companies Friday, 19 Sep 2014 | 6:02 PM ET

    Amgen Inc. rose $1.99 or 1.4 percent, to $144.01. Biogen Idec fell$. 75 or. 2 percent, to $329.24. Celgene Corp. rose$. 58 or. 6 percent, to $93.85.

  • Midday Glance: Biotechnology companies Friday, 19 Sep 2014 | 1:33 PM ET

    Amgen Inc. rose $1.46 or 1.0 percent, to $143.48. Biogen Idec fell $2.09 or. 6 percent, to $327.90. Celgene Corp. rose$. 29 or. 3 percent, to $93.56.

  • Early Glance: Biotechnology companies Friday, 19 Sep 2014 | 10:16 AM ET

    Amgen Inc. rose$. 83 or. 6 percent, to $142.85. Biogen Idec rose $3.80 or 1.2 percent, to $333.79. Celgene Corp. rose$. 90 or 1.0 percent, to $94.17.

  • Final Glance: Biotechnology companies Thursday, 18 Sep 2014 | 6:04 PM ET

    Amgen Inc. rose $1.31 or. 9 percent, to $142.02. Biogen Idec rose $2.41 or. 7 percent, to $329.99. Celgene Corp. rose $1.01 or 1.1 percent, to $93.27.

  • Midday Glance: Biotechnology companies Thursday, 18 Sep 2014 | 1:18 PM ET

    Amgen Inc. rose$. 60 or. 4 percent, to $141.31. Biogen Idec rose $1.08 or. 3 percent, to $328.66. Celgene Corp. rose$. 66 or. 7 percent, to $92.92.

  • Most active Nasdaq-traded stocks Thursday, 18 Sep 2014 | 1:18 PM ET

    Apple Inc. rose. 2 percent to $101.79 with 35,902,100 shares traded. Facebook Inc. rose. 7 percent to $77.00 with 22,472,500 shares traded. Gilead Sciences Inc. rose 2.0 percent to $105.93 with 16,071,400 shares traded.

  • Final Glance: Biotechnology companies Wednesday, 17 Sep 2014 | 6:04 PM ET

    Amgen Inc. rose $1.38 or 1.0 percent, to $140.71. Biogen Idec rose$. 70 or. 2 percent, to $327.58. Celgene Corp. fell$. 31 or. 3 percent, to $92.26.

  • Rackspace and Lennar are big market movers Wednesday, 17 Sep 2014 | 4:22 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:. United States Steel Corp., up $4.20 to $45.61. Rackspace Hosting Inc., down $6.95 to $32.39.

  • Midday Glance: Biotechnology companies Wednesday, 17 Sep 2014 | 1:17 PM ET

    Amgen Inc. rose$. 55 or. 4 percent, to $139.88. Biogen Idec fell $1.90 or. 6 percent, to $324.98. Celgene Corp. fell$. 66 or. 7 percent, to $91.91.

  • Early Glance: Biotechnology companies Wednesday, 17 Sep 2014 | 10:29 AM ET

    Amgen Inc. rose$. 10 or. 1 percent, to $139.43. Biogen Idec rose$. 86 or. 3 percent, to $327.74. Celgene Corp. fell$. 02 or percent, to $92.55.

  • Study shows downward trend in Sovaldi utilization Wednesday, 17 Sep 2014 | 8:38 AM ET

    Sept 17- Over the last several months there has been a' plateau and downward trend' in the use of Gilead Sciences Inc's controversial $1,000- a-pill hepatitis C treatment, Sovaldi, a CVS Health Corp analysis showed. The CVS Health Research Institute analyzed discontinuation rates for nearly 2,000 patients who filled prescriptions for Sovaldi since December.

  • UPDATE 1-Gilead's experimental drug fails mid-stage study Wednesday, 17 Sep 2014 | 6:47 AM ET

    Sept 17- Gilead Sciences Inc said its experimental drug did not significantly improve how long patients with a type of pancreatic cancer lived without the disease worsening. Separately, the biotechnology company also licensed Sovaldi to seven India- based drugmakers that will sell far cheaper versions of the drug in 91 developing nations.

  • GILEAD'S EXPERIMENTAL CANCER DRUG FAILS IN MID-STAGE STUDY@. Sept 17- Gilead Sciences Inc said its experimental drug did not significantly improve the length of time that patients with a type of pancreatic cancer lived without the disease worsening.

  • Final Glance: Biotechnology companies Tuesday, 16 Sep 2014 | 7:46 PM ET

    Amgen Inc. rose $1.36 or 1.0 percent, to $139.33. Biogen Idec rose $6.76 or 2.1 percent, to $326.88. Celgene Corp. rose $3.11 or 3.5 percent, to $92.57.

  • Midday Glance: Biotechnology companies Tuesday, 16 Sep 2014 | 1:22 PM ET

    Amgen Inc. rose$. 64 or. 5 percent, to $138.61. Biogen Idec rose $6.32 or 2.0 percent, to $326.44. Celgene Corp. rose $2.78 or 3.1 percent, to $92.24.

  • Early Glance: Biotechnology companies Tuesday, 16 Sep 2014 | 10:43 AM ET

    Amgen Inc. fell$. 22 or. 2 percent, to $137.75. Biogen Idec rose $4.12 or 1.3 percent, to $324.24. Celgene Corp. rose $1.18 or 1.3 percent, to $90.64.

  • Final Glance: Biotechnology companies Monday, 15 Sep 2014 | 6:03 PM ET

    Amgen Inc. rose$. 08 or. 1 percent, to $137.97. Biogen Idec fell $3.27 or 1.0 percent, to $320.12. Celgene Corp. fell $2.06 or 2.3 percent, to $89.46.